This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

44/100

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

There has been no extensive characterization of the effects of Ginsenoside Rg1, a pharmacological active component purified from the nature product ginseng, in an Alzheimer's disease mouse model. The well-characterized transgenic Alzheimer disease (AD) mice over expressing amyloid precursor protein (APP)/Aβ (Tg mAPP) and nontransgenic (nonTg) littermates at age of 6 and 9 months were treated with Rg 1 for three months via intraperitoneal injection. Mice were then evaluated for changes in amyloid pathology, neuropathology and behavior.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fang, F., Chen, X., Huang, T., Lue, L. F., Luddy, J. S., & Yan, S. S. (2012). Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochimica et biophysica acta. https://doi.org/10.1016/j.bbadis.2011.10.004

Vancouver

Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochimica et biophysica acta. 2012. doi:10.1016/j.bbadis.2011.10.004. PMID: 22015470.

BibTeX

@article{fang2012-22015470,
  author  = {Fang, F. and Chen, X. and Huang, T. and Lue, L. F. and Luddy, J. S. and Yan, S. S.},
  title   = {{Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model}},
  journal = {Biochimica et biophysica acta},
  year    = {2012},
  doi     = {10.1016/j.bbadis.2011.10.004},
  pmid    = {22015470},
  url     = {https://doi.org/10.1016/j.bbadis.2011.10.004}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

The well-characterized transgenic Alzheimer disease (AD) mice over expressing amyloid precursor protein (APP)/Aβ (Tg mAPP) and nontransgenic (nonTg) littermates at age of 6 and 9 months were treated with Rg 1 for three months via intraperitoneal injection.
Mice were then evaluated for changes in amyloid pathology, neuropathology and behavior.
Tg mAPP treated with Rg1 showed a significant reduction of cerebral Aβ levels, reversal of certain neuropathological changes, and preservation of spatial learning and memory, as compared to vehicle-treated mice.
Rg1 treatment inhibited activity of γ-secretase in both Tg mAPP mice and B103-APP cells, indicating the involvement of Rg1 in APP regulation pathway.

Why it matters

In transgenic Alzheimer mice, Ginsenoside Rg1 reduced cerebral amyloid-beta levels, reversed some neuropathological changes and preserved spatial memory. This is animal work and does not show benefit in patients.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Evidence strengthLow

How this study scored 44/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 42 of the 96 points we could judge it on, which is 44 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Biochimica et biophysica acta)
Journal's citation record	— / 4	No journal record from OpenAlex — left out of this score
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2012 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Laboratory or animal study (title names “mouse”) — scores zero
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 160 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	10.0 citations a year over 16 year(s) since 2012
Impact for its field and year	3 / 6	Cited 4.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	2 / 4	Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Shirley ShiDu Yan: h-index 52 (OpenAlex, whole career)
Institution's track record	2 / 3	Columbia University: institution h-index 1,824 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 22015470)
Free to read	0 / 2	Behind a paywall — scores zero
Points	42 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 42 of the 96 points we could judge it on is 44 out of 100.
Total	44 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Risk genes beyond APOE

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →